title: Severe Obesity Impacts Recurrence-Free Survival of Women with High-Risk Endometrial Cancer: Results of a French Multicenter Study.
abstract: BACKGROUND
  Studies focusing on the impact of obesity on survival in endometrial cancer (EC) have reported controversial results and few data exist on the impact of obesity on recurrence rate and recurrence-free survival (RFS). The aim of this study was to assess the impact of obesity on surgical staging and RFS in EC according to the European Society of Medical Oncology (ESMO) risk groups.
  
  
  METHODS
  Data of 729 women with EC who received primary surgical treatment between January 2000 and December 2012 were abstracted from a multicenter database. RFS distributions according to body mass index (BMI) in each ESMO risk group were estimated using the Kaplan-Meier method. Survival was evaluated using the log-rank test, and the Cox proportional hazards model was used to determine influence of multiple variables.
  
  
  RESULTS
  Distribution of the 729 women with EC according to BMI was BMI < 30 (n = 442; 60.6 %), 30 ≤ BMI < 35 (n = 146; 20 %) and BMI ≥ 35 (n = 141; 19.4 %). Nodal staging was less likely to be performed in women with a BMI ≥ 35 (72 %) than for those with a BMI < 30 (90 %) (p < 0.0001). With a median follow-up of 27 months (interquartile range 13-52), the 3-year RFS was 84.5 %. BMI had no impact on RFS in obese women in the low-/intermediate-risk groups, but a BMI ≥ 35 was independently correlated to a poorer RFS (hazard ratio 12.5; 95 % confidence interval 3.1-51.3) for women in the high-risk group.
  
  
  CONCLUSIONS
  Severe obesity negatively impacts RFS in women with high-risk EC, underlining the importance of complete surgical staging and adapted adjuvant therapies in this subgroup of women.
authors.affiliation: Department of Obstetrics and Gynaecology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), Paris, France, geoffroy.canlorbe@wanadoo.fr.
authors.forename: Geoffroy
authors.initials: G
authors.lastname: Canlorbe
authors.forename: Sofiane
authors.initials: S
authors.lastname: Bendifallah
authors.forename: Emilie
authors.initials: E
authors.lastname: Raimond
authors.forename: Olivier
authors.initials: O
authors.lastname: Graesslin
authors.forename: Delphine
authors.initials: D
authors.lastname: Hudry
authors.forename: Charles
authors.initials: C
authors.lastname: Coutant
authors.forename: Cyril
authors.initials: C
authors.lastname: Touboul
authors.forename: Géraldine
authors.initials: G
authors.lastname: Bleu
authors.forename: Pierre
authors.initials: P
authors.lastname: Collinet
authors.forename: Emile
authors.initials: E
authors.lastname: Darai
authors.forename: Marcos
authors.initials: M
authors.lastname: Ballester
mesh_terms: D000368:Aged; D015992:Body Mass Index; D002277:Carcinoma / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D002296:Carcinosarcoma / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D053208:Kaplan-Meier Estimate; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D009765:Obesity / Q000150:complications* / Q000401:mortality; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors